Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc.

CourtDistrict Court, N.D. California
DecidedDecember 20, 2023
Docket3:22-cv-01759
StatusUnknown

This text of Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc. (Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc., (N.D. Cal. 2023).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 GENOMMA LAB INTERNACIONAL, Case No. 3:22-cv-01759-WHO S.A.B. DE C.V., 8 Plaintiff, ORDER ON MOTION TO DISMISS 9 AND STRIKE THIRD AMENDED v. COMPLAINT 10 MPREZAS, INC., et al., Re: Dkt. No. 87 11 Defendants.

12 13 Plaintiff Genomma Lab Internacional, S.A.B. de C.V. (“Genomma”) filed this trademark 14 infringement suit against defendants Mprezas, Inc.; iBrand Holdings, LLC; OPMX, LLC; Martha 15 Nancy Hernandez; and Fernando Eduardo Bedoy Garces (collectively, “the defendants”). In its 16 third amended complaint, Genomma newly asserts that the defendants fraudulently procured 17 registration of their TWKOF and TUTOX trademarks. The defendants move to dismiss those new 18 claims, move to dismiss all claims against Bedoy Garces, and move to strike several allegations in 19 the operative complaint. For the following reasons, the motion is granted in part and denied in 20 part. 21 BACKGROUND 22 The factual background of this case is laid out in my Prior Order, [Dkt. No. 83], and this 23 Order assumes familiarity with those facts, which are repleaded in the Third Amended Complaint 24 (“TAC”), [Dkt. No. 86]. In a nutshell, Genomma asserts that the defendants’ TWKOF and 25 TUTOX marks, labels, and products infringe on Genomma’s trademark and copyright for its 26 TUKOL cough medicine products. See Prior Order Background. Additional relevant facts from 27 the TAC are as follows. 1 applied to the United States Patent and Trademark Office (“USPTO”) for a trademark because she 2 used a W and an F in the registration but the label itself appears to use a U and an L. TAC ¶¶ 89, 3 91. Genomma also says that Hernandez falsely told the USPTO that she did not know of other 4 confusingly similar marks used in commerce. Id. ¶¶ 90-92. According to Genomma, this was all 5 because Hernandez intended to deceive the USPTO. Id. ¶ 30. Genomma alleges that the USPTO 6 “accepts” but “does not verify” information in the registrations provided by the applications. Id. 7 ¶¶ 90-91, 93. 8 Genomma also appears to assert that before selling the TWKOF or TUTOX products, the 9 defendants were required to register with the Food and Drug Administration (“FDA”) and receive 10 a “National Drug Code.” Id. ¶¶ 47-48, 52-55. It states that the defendants did not do so for 11 TUTOX at least as of February 27, 2023, yet Hernandez submitted a sworn declaration to the 12 USPTO that the mark was used in commerce at least by that date. See id. ¶ 107-10. Genomma 13 further alleges that the TUTOX packaging label provided to the USPTO in the application was not 14 the real TUTOX label but rather an edited version of the TWKOF label designed to help the 15 defendants register the mark. Id. 16 Additionally, Genomma alleges that individual defendant Fernando Eduardo Bedoy 17 Garces1 is the sole manager and employee of iBrand, a Wyoming LLC, and the sole owner and 18 manager of OPMX, a Delaware LLC. Id. ¶¶ 10, 12, 15-16. It asserts that Bedoy Garces did not 19 provide his location of residence during his deposition, but it believes he lives in Southern 20 California due to conditions of his current probation. Id. ¶ 14. 21 According to Genomma, Mprezas assigned its TWKOF trademark to iBrand in April 2022. 22 Id. ¶ 39. Bedoy Garces signed the agreement and filed the assignment with the USPTO. Id. 23 Genomma alleges that at that time, Bedoy Garces knew that the TWKOF mark was being misused 24 to confuse and deceive customers. Id. ¶ 40. It asserts that OPMX, and therefore Bedoy Garces, 25 are responsible for the TWKOF design. Id. ¶¶ 61-63. 26 27 1 The TAC asserts six causes of action: (1) trademark infringement under 15 U.S.C. § 1114,2 2 id. ¶¶ 64-72; (2) unfair competition under 15 U.S.C. § 1125(a)(1)(A), id. ¶¶ 73-78; (3) trade dress 3 infringement, id. ¶¶ 79-86; (4) fraudulent procurement of the TWKOF mark under 15 U.S.C. 4 § 1064, id. ¶¶ 87-96; (5) copyright infringement under 17 U.S.C. §§ 101 et seq., id. ¶¶ 97-103; and 5 (6) fraudulent procurement of the TUTOX mark under 15 U.S.C. § 1064, id. ¶¶ 105-13. 6 The defendants filed a motion to dismiss the two fraudulent procurement claims and all 7 claims against Bedoy Garces, as well as a motion to strike certain allegations in the TAC and two 8 requests for judicial notice. (“Mot.”) [Dkt. No. 87]. Genomma opposed. (“Oppo.”) [Dkt. No. 9 89]. The defendants replied. (“Repl.”) [Dkt. No. 90]. I held a hearing at which counsel for both 10 parties appeared. 11 LEGAL STANDARD 12 I. RULE 12(B)(6) 13 Under Federal Rule of Civil Procedure (“FRCP”) 12(b)(6), a district court must dismiss a 14 complaint if it fails to state a claim upon which relief can be granted. To survive a Rule 12(b)(6) 15 motion to dismiss, the plaintiff must allege “enough facts to state a claim to relief that is plausible 16 on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim is facially plausible 17 when the plaintiff pleads facts that “allow the court to draw the reasonable inference that the 18 defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) 19 (citation omitted). There must be “more than a sheer possibility that a defendant has acted 20 unlawfully.” Id. While courts do not require “heightened fact pleading of specifics,” a plaintiff 21 must allege facts sufficient to “raise a right to relief above the speculative level.” Twombly, 550 22 U.S. at 555, 570. 23 In deciding whether the plaintiff has stated a claim upon which relief can be granted, the 24 Court accepts the plaintiff’s allegations as true and draws all reasonable inferences in favor of the 25 plaintiff. See Usher v. City of Los Angeles, 828 F.2d 556, 561 (9th Cir. 1987). However, the court 26

27 2 As noted in my Prior Order, Genomma cites 15 U.S.C. § 1114(a), though it seems that it 1 is not required to accept as true “allegations that are merely conclusory, unwarranted deductions of 2 fact, or unreasonable inferences.” In re Gilead Scis. Sec. Litig., 536 F.3d 1049, 1055 (9th Cir. 3 2008). 4 If the court dismisses the complaint, it “should grant leave to amend even if no request to 5 amend the pleading was made, unless it determines that the pleading could not possibly be cured 6 by the allegation of other facts.” Lopez v. Smith, 203 F.3d 1122, 1127 (9th Cir. 2000). In making 7 this determination, the court should consider factors such as “the presence or absence of undue 8 delay, bad faith, dilatory motive, repeated failure to cure deficiencies by previous amendments, 9 undue prejudice to the opposing party and futility of the proposed amendment.” Moore v. Kayport 10 Package Express, 885 F.2d 531, 538 (9th Cir. 1989). 11 II. RULE 9(B) 12 FRCP 9(b) imposes a heightened pleading standard where a complaint alleges fraud or 13 mistake.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. Corinthian Colleges
655 F.3d 984 (Ninth Circuit, 2011)
United States v. J. Alexis Caparros
800 F.2d 23 (Second Circuit, 1986)
Nazzaro Scarpa v. Larry E. Dubois, Etc.
38 F.3d 1 (First Circuit, 1994)
Kearns v. Ford Motor Co.
567 F.3d 1120 (Ninth Circuit, 2009)
In Re Gilead Sciences Securities Litigation
536 F.3d 1049 (Ninth Circuit, 2008)
Rosales v. Citibank, Federal Savings Bank
133 F. Supp. 2d 1177 (N.D. California, 2001)
Platte Anchor Bolt, Inc. v. IHI, INC.
352 F. Supp. 2d 1048 (N.D. California, 2004)
Aureflam Corp. v. Pho Hoa Phat I, Inc.
375 F. Supp. 2d 950 (N.D. California, 2005)
eCash Technologies, Inc. v. Guagliardo
210 F. Supp. 2d 1138 (C.D. California, 2001)
Hokto Kinoko Company v. Concord Farms, Inc.
738 F.3d 1085 (Ninth Circuit, 2013)
United States v. Ayala-Vazquez
751 F.3d 1 (First Circuit, 2014)
Shahin v. Geithner
84 F. Supp. 3d 1 (District of Columbia, 2015)
Lien Huynh v. Chase Manhattan Bank
465 F.3d 992 (Ninth Circuit, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
Genomma Lab Internacional, S.A.B. de C.V. v. Mprezas, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/genomma-lab-internacional-sab-de-cv-v-mprezas-inc-cand-2023.